XTL Biopharmaceuticals Ltd ADR

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. Show More...

  • Website https://www.xtlbio.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 1.20 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -1.1 -0.6 -0.6 -1.1 -1.1 -1.7 -0.9 -0.2 0.6 -0.3 -1.09
    Dividends USD
    Payout Ratio % *
    Shares Mil 1.0 2.0 2.0 2.0 2.0 3.0 3.0 5.0 5.0 5.0 5.0
    Book Value Per Share * USD 1.48 1.82 3.2 3.14 1.97 2.64 1.39 0.7 1.41 1.57 1.37
    Free Cash Flow Per Share * USD -0.66 -0.37 -0.73 -1.16 -1.04 -0.84 -0.79 -0.44 -0.22 -0.16
    Return on Assets % -55.72 -30.67 -18.34 -25.93 -37.0 -78.62 -61.03 -16.27 39.39 -17.06 -52.72
    Financial Leverage (Average) 1.34 1.18 1.51 1.28 1.21 1.09 1.12 1.82 1.03 1.03 1.03
    Return on Equity % -88.49 -38.45 -25.75 -36.36 -46.26 -90.31 -67.2 -24.77 50.01 -17.61 -54.04
    Return on Invested Capital % -88.42 -38.99 -26.58 -36.51 -46.44 -90.31 -67.2 -25.28 48.89 -18.82 -54.04
    Interest Coverage -178.57 -171.43 -115.13
    Current Ratio 2.52 4.17 3.24 9.78 8.35 20.69 32.39 29.44 28.23
    Quick Ratio 2.48 3.77 2.25 9.33 7.41 20.35 32.1 29.0 17.45
    Debt/Equity